


Some hospitals in COVID-19 hotspots running short of remdesivir

July 14 2020



(HealthDay)—Some U.S. hospitals in COVID-19 hotspots are running

short of the antiviral drug remdesivir—the only drug authorized by the U.S. Food and Drug Administration to treat the disease—while hospitals in other regions have stocks of the drug that are going unused.

The [federal government](#) is overseeing distribution of remdesivir. In the coming week, allocations of remdesivir to states "will emphasize locations with large recent increases," a Department of Health and Human Services spokesperson told *CNN*.

But the amounts of the drug cited by the spokesperson to be shipped to four hotspot states—Arizona, California, Florida, and Texas—are far smaller than the number of hospitalized COVID-19 patients in those states.

The spokesperson also told *CNN* that the company hired to distribute remdesivir will contact each hospital that received the drug to confirm that it still needs it.

More information: [CNN Article](#)

Copyright © 2020 [HealthDay](#). All rights reserved.

Citation: Some hospitals in COVID-19 hotspots running short of remdesivir (2020, July 14) retrieved 25 April 2024 from <https://medicalxpress.com/news/2020-07-hospitals-covid-hotspots-short-remdesivir.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.